Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment

Gianluca Santonicola^*
*Correspondence: Gianluca Santonicola, Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA, Email:

Introduction

Curcumin, the active compound found in turmeric, has gained immense attention in recent years due to its potential health benefits. From its antioxidant and anti-inflammatory properties to its ability to modulate various signaling pathways implicated in disease progression, curcumin holds promise as a therapeutic agent for a wide range of ailments. However, its poor bioavailability has been a major challenge in harnessing its full potential. In this article, we delve into strategies aimed at enhancing the bioavailability and bioactivity of curcumin to maximize its efficacy in disease prevention and treatment [1].

Curcumin is a polyphenolic compound derived from the rhizome of the Curcuma longa plant, commonly known as turmeric. It has been used for centuries in traditional medicine systems such as Ayurveda and traditional Chinese medicine for its medicinal properties. Curcumin exhibits antioxidant, anti-inflammatory, antimicrobial, and anticancer activities, making it a promising candidate for various therapeutic applications [2]. Despite its remarkable therapeutic potential, curcumin has poor bioavailability when administered orally. Several factors contribute to this, including low solubility in water, rapid metabolism, and poor absorption in the gastrointestinal tract. As a result, the concentration of free curcumin in the bloodstream remains low, limiting its therapeutic efficacy.

Description

Nanotechnology-based delivery systems such as nanoparticles, liposomes, and micelles have been developed to improve the solubility and stability of curcumin. These nanocarriers protect curcumin from degradation and facilitate its transport across biological barriers, thereby enhancing its bioavailability. Piperine, a compound found in black pepper, has been shown to inhibit the enzymes responsible for curcumin metabolism, thereby increasing its bioavailability. Co-administration of curcumin with piperine has been found to significantly enhance curcumin absorption and bioavailability in preclinical and clinical studies. Lipid-based formulations such as solid lipid nanoparticles and nanoemulsions have been developed to improve the oral absorption of curcumin. By encapsulating curcumin in lipid matrices, these formulations enhance its solubility and protect it from degradation in the gastrointestinal tract, leading to improved bioavailability. Chemically modified curcumin analogues with enhanced bioavailability have been synthesized to overcome the limitations of native curcumin. These analogues retain the therapeutic properties of curcumin while exhibiting improved pharmacokinetic profiles, making them attractive candidates for drug development [3-5].

Studies investigating the pharmacokinetics and pharmacodynamics of enhanced curcumin formulations have demonstrated improved bioavailability and tissue distribution compared to native curcumin. These formulations exhibit prolonged circulation time, increased peak plasma concentrations, and enhanced target tissue accumulation, leading to superior therapeutic effects in preclinical models. Enhanced curcumin formulations hold great promise for the prevention and treatment of various diseases, including cancer, inflammatory disorders, neurodegenerative diseases, cardiovascular diseases, and metabolic syndromes. Clinical trials evaluating the safety and efficacy of these formulations are underway, with promising results reported in several studies. Future research efforts should focus on optimizing formulation strategies, elucidating the underlying mechanisms of action, and exploring novel therapeutic applications of enhanced curcumin formulations.

Conclusion

Enhancing the bioavailability and bioactivity of curcumin is essential for maximizing its therapeutic potential in disease prevention and treatment. Nanotechnology-based delivery systems, piperine co-administration, lipidbased formulations, and structural analogues represent promising strategies to overcome the challenges associated with curcumin bioavailability. Continued research and development in this field are crucial for harnessing the full therapeutic benefits of curcumin and translating them into clinical practice.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Strimpakos, Alexios S. and Ricky A. Sharma. "Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials."Antioxid Redox Signal 10 (2008): 511-546.

   Google Scholar, Crossref, Indexed at

2. Itaya, Mayuko, Taiki Miyazawa, Jean-Marc Zingg and Takahiro Eitsuka, et al. "The differential cellular uptake of curcuminoids in vitro depends dominantly on albumin interaction."Phytomedicine59 (2019): 152902.

   Google Scholar, Crossref, Indexed at

3. Epstein, Jenny, Ian R. Sanderson and Thomas T. MacDonald. "Curcumin as a therapeutic agent: The evidence from in vitro, animal and human studies."Br J Nutr 103 (2010): 1545-1557.

   Google Scholar, Crossref, Indexed at

4. Shehzad, Adeeb, Taewook Ha, Fazli Subhan and Young Sup Lee. "New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases."Eur J Nutr50 (2011): 151-161.

   Google Scholar, Crossref, Indexed at

5. Gupta, Subash C., Sridevi Patchva, Wonil Koh and Bharat B. Aggarwal. "Discovery of curcumin, a component of golden spice, and its miraculous biological activities."Clin Exp Pharmacol Physiol39 (2012): 283-299.

   Google Scholar, Crossref, Indexed at